Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics has posted revenues of $12.17m for the first quarter ended 31 March 2011, compared to $46.46m for the same period in 2010.
Subscribe to our email newsletter
The company reported a net loss of $32.67m, or $0.3 per diluted share, compared to a net income of $11.46m, or $0.11 per diluted share, for the same period last year.
Seattle Genetics‘ loss from operations was $32.98m, as compared to $10.91m for the same period prior year.
Seattle Genetics president and CEO Clay Siegall said the recent action by FDA to accept for filing their Biologics License Applications for brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma mark a significant regulatory milestone for the program.
"With more than $455m in cash and investments, we are well-positioned to continue executing on our commercial and development plans," Siegall said.